PARK2
, 8 SUFU, 8 and ZNF217 3 . 8, 10 With these genes in mind, perhaps there are at least 20 GIST subtypes. In fact, there are still some tumors with mutations/epimutations that remain to be discovered. Thus, the GIST research community has begun to tame these "quadruple WT" tumors by adding 9 more genes to the list of putative drivers.
Despite the aforementioned progress, clinicians, scientists, and patients continue to call these tumors "WT," with additional subcategorization by SDHB protein expression. However, it is becoming clearer that none of these are WT, and continuing to call them this is a misnomer. It pays no homage to the genetic diversity of GIST, nor is it molecularly accurate. These tumors do have mutations/epimutations, and phenotypically, these patients do have a cancer. Thus, they and their tumors are not WT. 11 We have now begun to domesticate these WT GISTs, and we need to be clear and accurate in our terminology because there are associated treatment implications. Unless there is normal SDHB protein expression and a lack of alterations on wholegenome (ie, mutation analysis), whole-genome bisulfite (ie, methylation analysis), and RNA sequencing (ie, RNA expression analysis), these tumors are not WT. Their driver genes and genomic alterations are just yet to be determined.
Because KIT and PDGFRA mutant tumors constitute the majority of GIST, the remaining 20 genetic subtypes constitute the minority. We call to abandon the term "WT" and propose "unclassified" GIST as a name for any unknown GIST subtypes. In cases where the mutation is undetermined, we should denote them by their SDHB immunostaining and the GIST driver genes, which lack alterations. For example, an SDHB-competent case without mutations discovered on the Oregon Health & Science University GeneTrails GIST Genotyping Panel (ie, AKT1, AKT2, AKT3, ATM, BRAF, CDKN2A, HRAS, KIT, KRAS, MAP2K1, NF1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, SDHA, SDHAF1, SDHAF2, SDHB, SDHC, SDHD, and TP53) would still need to be qualified as an "unclassified" GIST, because several aforementioned genes or kinase fusions are not included in this panel. 8 Clarity in name and description of genomic alterations are critical to moving this field forward. This may have clinical implications for more precisely designing clinical trials and crafting personalized treatment regimens with FDA-approved and/or experimental agents (Table 1) . Based on the genomic alterations, theoretical precision actionabilities may be assigned and potentially nonefficacious therapies may be avoided.
In conclusion, emerging work has provided increasing insights into the pathobiology of GIST subtypes. We are increasingly stratifying GISTs into distinct groups based on tumor genomics, and these do have clear clinical implications. By cultivating new nomenclature and taming terms like "WT" GISTs, we will continue
